Medici per Melanoma all'estero — Pagina 3

Dr. Nail Paksoy is an associate professor of medical oncology at Medipol Bahçelievler Hospital. He is board-certified by the European Society for Medical Oncology (ESMO). Dr. Paksoy specializes in lung, breast, and gastrointestinal cancers. He uses modern immunotherapy and targeted therapy protocols. His clinic is JCI-accredited for high safety standards.

• Served as a subinvestigator in over 8 international clinical trials for Roche and Pfizer.
• Authored over 40 research articles in journals indexed by SCI and SSCI.
• Completed dual fellowships in allergy-immunology and medical oncology.
• Treats complex sarcomas and renal cell carcinomas with systemic therapies.

Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.

He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.

His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.

Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).

Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).

He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.

Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.

Dr. Mariam Mohammed Hussein Abu Zeid is a clinical oncologist. She treats solid tumors and hematologic cancers. She earned her MBBCh from Ain Shams University in 2007 (Excellent). She completed a Master’s in Clinical Oncology and Nuclear Medicine in 2011 (Very Good). She received a Ph.D. in 2018 and an ESMO Certificate in 2015.

She leads and monitors clinical trials. Her work includes data collection and analysis. She administers chemotherapy and manages treatment toxicities. She also plans care with multidisciplinary teams. Her experience includes Ain Shams University Hospitals (2009–2012), the International Medical Center (2012–2014), and Wadi El Nile Hospital (2015–2019). Her roles covered diagnosis and staging, supportive care, quality improvement, and screening. She educates patients and families about the diagnosis, treatment options, and palliative care.

Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

Dr. Mustafa Serkan Alemdar is a clinical oncologist at Medical Park Antalya Hospital Complex. He specializes in treating complex solid tumors and blood cancers. Dr. Alemdar completed his medical degree and oncology fellowship at Akdeniz University. He is an active member of the Turkish Society of Medical Oncology.

• Treats a wide range of cancers including breast, lung, and prostate.
• Expert in hematology-oncology for conditions like leukemia, myeloma, and lymphoma.
• Performs systemic therapies such as chemotherapy, immunotherapy, and targeted biological therapy.
• Works at a facility that houses specialized oncology-bone marrow units and LINAC technology.

Dr. Theodoulos Drousiotis is a dermatovenereologist at the German Medical Institute in Cyprus. He completed a Senior Skin Cancer Fellowship at St John’s Institute of Dermatology in London. Dr. Drousiotis specializes in melanoma screening, skin surgery, and aesthetic rejuvenation. He is a member of the European Academy of Dermatology and Venereology.

• Trained at Sheba Medical Centre, a facility often ranked among the best globally.
• Treats skin cancers, including basalioma and melanoma, using digital dermoscopy and mole mapping.
• Performs aesthetic procedures like Morpheus8, hyaluronic acid fillers, and laser scar removal.
• Teaches medical students at King’s College London and the University of Glasgow.

Specializations

Cancer Surgery

Pancreatic Surgery

Bile Duct Surgery

Bariatric Metabolic Surgery

Oncological Surgery

Breast Surgery

Gastric cancer

Colon cancer

Thyroid Cancer

Obesity Surgery

Diabetes Surgeries

Dr. Emad Shash, M.B.B.Ch, MSc, M.D., is a medical oncologist. He is the Medical Director of the Breast Comprehensive Cancer Hospital at NCI. He leads the Medical Oncology Department and is the Breast Program Director at Shifaa Al Orman Cancer Hospital in Luxor. His clinical focus includes breast, gynecologic, genitourinary, thoracic, gastrointestinal, and rare cancers. He specializes in systemic therapy, including chemotherapy, targeted therapy, and immunotherapy.

He served as coordinating research physician and medical lead at the EORTC from 2011 to 2015. Since 2008, he has contributed to more than 70 international oncology trials as a coordinator, sub-investigator, principal investigator, and sponsor medical monitor. Credentials include M.B.B.Ch (2004), MSc (2010), MD (2015), and the EORTC Certificate of Excellence (2015). He also holds a Diploma in Hospital Quality Management & Patient Safety (JCI/57357, 2017). He is a Fellow of the EIO. He is a member of ESMO (panel voting), ESGO, and ASCO (IAC), and serves on the ECRIN board.

Dr. Erkan Karatas is an ENT and maxillofacial surgeon at Atlas University Hospital in Istanbul. He specializes in skull base surgery and cochlear implant placement. Dr. Karatas has contributed to over 100 medical articles. He completed specialized training at prestigious centers in the US, Germany, Italy, and Switzerland.

• Member of 11 professional associations, including the American Academy of Otolaryngology.
• Expert in complex surgeries for thyroid, tongue, and larynx cancers.
• Performs specialized procedures like stapedectomy, tympanoplasty, and orthognathic surgery.
• Works at an AACI-accredited hospital that treats 565,000 patients annually.

Dr. Mohamed Mahmoud Abdelhakim is Head of Radiation Oncology at Shefa al Orman Hospital, Luxor. He is Professor of Radiation Oncology at the National Cancer Institute, Cairo University. He previously served as Associate Professor (2015–2020), Lecturer (2010–2015), Assistant Lecturer (2003–2009), and Resident (2000–2003). He also worked as a Specialist at Gharbia Cancer Society.

He treats inpatients and outpatients with breast, soft tissue sarcoma, lymphoma, gynecologic, gastrointestinal, genitourinary, and CNS tumors. His skills include image-guided brachytherapy, IMRT, VMAT, SRS, and SBRT. He performs conventional and CT-based planning and 3D-CRT. He works with cobalt and linear accelerators and electron beam therapy. He provides HDR and LDR intracavitary and interstitial brachytherapy. He also performs stereotactic radiotherapy, total body irradiation, and total skin irradiation.

Member: Egyptian Cancer Society, ESTRO, ESMO.

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.

Dr. Maha Yahia is a medical oncologist and hemato-oncologist. She provides assessment, diagnosis, and treatment planning. Her treatments include chemotherapy, targeted therapy, and immunotherapy. She cares for patients with breast, genitourinary, gynecologic, thoracic, gastrointestinal, and rare cancers.

Education: M.B.B.Ch, Kasr El-Aini, Cairo University (1997–2003). Master in Hemato-oncology, National Cancer Institute, Cairo University (2008). Doctoral Degree in Hemato-oncology, National Cancer Institute, Cairo University (2015).

Experience: Resident in Medical Oncology, Maadi AFMC (2005–2010). Visitor Resident, NCI Cairo (2008–2009). Consultant Assistant, Prof. Hussein Khaled Clinic (2010–2017). Specialist, International Medical Center (2011–2012), Wadi El Nile Hospital (2013–2014), and Maadi AFMC (2011–2018). Head, Clinical Research Support Team, Maadi AFMC (2016–2018). Major (2014–2016) and Lt. Colonel Doctor (2016–2018), Egyptian Armed Forces. Lecturer of Clinical Research, AFCM (2019–2021).

Uzm. Dr. Erkan Göcen is a Radiation Oncology Specialist at Çerkezköy Private Optimed Hospital (Optimed Health Group). He graduated from İstanbul University, İstanbul Faculty of Medicine (Çapa) in 2003.

Career: He trained and practiced in Radiation Oncology from 2010 to 2012. He worked in public and private health institutions from 2012 to 2016. He served in the private medical sector as a Radiation Oncology Specialist from 2016 to 2023. He has been at Optimed Hospital since 2024.

Clinical interests: cancers of the brain, head and neck, esophagus, stomach, colorectal, pancreas, prostate, bladder, lung, soft tissues (sarcomas), skin, uterus and cervix, and breast. Affiliations: Turkish Society for Radiation Oncology (TROD) and Tekirdağ Medical Chamber. Languages: English and Turkish.

Il medico è specializzato nel trattamento del cancro al seno e endocrino, concentrandosi sul superamento della resistenza alla terapia ormonale durante la malattia adiuvante e metastatica. Attivamente coinvolto in studi di fase 1, 2 e 3 per il cancro al seno e il melanoma, il medico ha contribuito all'approvazione di nuovi farmaci, inclusi inibitori di cdk4/6 come palbociclib e ribociclib per il cancro al seno metastatico, e trattamenti di immunoterapia come Pembrolizumab, Nivolumab e Ipilimumab per il melanoma. Il medico è membro dell'Unità di Cancro al Seno e dell'Unità di Melanoma presso l'Ospedale Universitario Vall d’Hebron e l'Istituto di Oncologia Vall d’Hebron.<\/p>

Il medico dirige il Centro di Melanoma e Immunoterapia del Cancro presso il Centro Medico Hadassah, concentrandosi sulla ricerca innovativa e sul trattamento dei pazienti. Specializzandosi nello studio della famiglia dei recettori SLAM, il medico è in prima linea nella ricerca sulla risposta immunitaria anti-cancro.<\/p>

Coinvolto nel trattamento dei pazienti con melanoma con nuove immunoterapie, il medico lavora con un team di clinici e ricercatori. Questa collaborazione fornisce accesso immediato ai dati clinici e ai tessuti derivati dai pazienti, migliorando gli sforzi di ricerca traslazionale.<\/p>

Il medico è un oncologo altamente esperto con un focus sul trattamento e la gestione del cancro. Con anni di pratica dedicata, il medico ha contribuito in modo significativo ai progressi in oncologia, implementando terapie all'avanguardia e partecipando a ricerche volte a migliorare i risultati dei pazienti. Il medico è riconosciuto per la sua leadership all'interno della comunità oncologica, avendo ricoperto ruoli chiave che guidano l'innovazione e la cura di qualità nel trattamento del cancro. La loro esperienza clinica è completata da un impegno per la cura centrata sul paziente e lo sviluppo professionale continuo.<\/p>